PVLA Competitors & Alternatives

Compare Palvella Therapeutics, Inc with similar stocks in the same industry

Biotechnology

PVLA

Main Stock
$145.03
-4.89%
Tradestie Score
49
Market Cap
$699.30M
Analyst Upside
+61.2%

Supply-Chain & Ecosystem Map (Customers, Suppliers & Direct Competitors)

Bottleneck Score: 2/10 Drug Discovery Biotech Drug Design
Competitive Moat: None
Core Technology Stack: topical rapamycin formulation, anhydrous gel delivery system
Major Customers 5
specialty pharmacies dermatology clinics rare disease patients academic medical centers biopharma partners
Critical Suppliers 5
contract manufacturing organizations API suppliers for rapamycin clinical research organizations regulatory consultants cold-chain logistics providers
Direct Ecosystem Rivals 3

Top Competitors

215 stocks in Biotechnology
Company Price Market Cap P/E Score Action
ARQT Arcutis Biotherapeutics, Inc. Common Stock
$27.19
-3.79%
$2.37B 125.1 62 Compare
APGE Apogee Therapeutics, Inc. Common Stock
$135.07
-0.01%
$2.35B - 54 Compare
IBRX ImmunityBio, Inc. Common Stock
$6.03
+0.08%
$2.34B - 50 Compare
IRON Disc Medicine, Inc. Common Stock
$77.72
-2.86%
$2.33B - 47 Compare
AGIO Agios Pharmaceuticals, Inc.
$30.42
-3.70%
$2.33B - 59 Compare
GLPG Galapagos NV
$27.73
-3.75%
$2.31B 5.1 47 Compare
RXRX Recursion Pharmaceuticals, Inc. Class A Common Stock
$2.91
-8.79%
$2.23B - 50 Compare
ADPT Adaptive Biotechnologies Corporation Common Stock
$28.00
-3.58%
$2.22B - 45 Compare
TVTX Travere Therapeutics, Inc. Common Stock
$49.90
-1.48%
$2.21B - 59 Compare
DNLI Denali Therapeutics Inc. Common Stock
$18.33
-2.19%
$2.18B - 51 Compare

Data updated: Nov 16, 2026 | Industry: Biotechnology (SIC 2834)

215 stocks in this industry